BioTissue names Rocco Venezia chief financial officer
BioTissue has appointed Rocco Venezia, CPA, as chief financial officer, replacing longtime CFO Mike Cornelius after 13 years. The hire brings in a finance executive with public-company, fundraising and transaction experience as BioTissue looks to support growth in eye care and regenerative healing.
Why it matters: - BioTissue is adding a CFO with experience in finance transformation, capital management and fundraising as the company scales its regenerative healing business. - The leadership change comes as longtime CFO Mike Cornelius retires after 13 years, marking a major finance transition at the company.
What happened: - BioTissue announced the appointment of Rocco Venezia, CPA, as chief financial officer. - Venezia joins BioTissue from Intercept Pharmaceuticals, where he most recently served as CFO. - Ted Davis, BioTissue president and CEO, said Venezia’s experience will support the company’s growth and mission. - Venezia said he is excited to join BioTissue and support its continued growth and long-term success.
The details: - Venezia led enterprise-wide finance operations, strategic planning, capital management and financial transformation at Intercept. - During 10 years at Intercept, Venezia moved through multiple leadership roles, including corporate controller, before becoming CFO. - His career includes fundraising efforts exceeding $1.3 billion. - Venezia has supported IPO and M&A transactions and worked closely with executive teams and boards. - Before Intercept, Venezia held finance and accounting leadership roles at Mallinckrodt Pharmaceuticals and KPMG. - Venezia earned a Bachelor of Science in Accounting from Kean University. - BioTissue describes itself as a leader in regenerative healing across the ocular surface disease continuum.
Between the lines: - BioTissue is signaling that it wants finance leadership with public-company discipline and capital markets experience. - The company appears to be prioritizing operational scale and sustainable growth as it advances its eye-care mission.
What's next: - Venezia is expected to help guide BioTissue’s finance strategy, capital planning and growth efforts. - Cornelius’ retirement closes a long CFO tenure and opens a new phase for the company’s financial leadership.
The bottom line: - BioTissue is swapping in an experienced finance operator as it looks to strengthen its platform and grow the business.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
Technology News Journal
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.